Post hoc subgroup analysis of ONCO PE (178 patients with cancer-associated low-risk PE): 18 vs 6 months of rivaroxaban lowered recurrent VTE with performance status 0 (2.7% vs 19.0%) but not significantly with PS 1 or more (7.7% vs 19.1%).
Secondary analysisn = 178
Xiong et al. Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial